Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

Joshua K. Sabari; Vamsidhar Velcheti; K. Shimizu; Matthew R. Strickland; Rebecca S. Heist; Mohini Singh; Naema Nayyar; Anita Giobbie‐Hurder; Subba R. Digumarthy; Justin F. Gainor; Anant P. Rajan; Edwin Nieblas‐Bedolla; Aaron C. Burns; Jill Hallin; Peter Olson; James G. Christensen; Sylvia C. Kurz; Priscilla K. Brastianos; Hiroaki Wakimoto

doi:10.1158/1078-0432.ccr-22-0383

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

These data support further development of adagrasib in patients with KRASG12C-mutant NSCLC with untreated BM. See related commentary by Kommalapati and Mansfield, p. 3179.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sabari et al. (2022) studied this question.

synapsesocial.com/papers/69db1d5937b5141e3ba3cd5b https://doi.org/10.1158/1078-0432.ccr-22-0383

View Full Paper

Ask AI

Bookmark

Share

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading